Navigation Links
InterMune to Release Second Quarter Financial Results on July 27

BRISBANE, Calif., July 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will release second quarter 2010 financial results on Tuesday, July 27, 2010 at 4:00 p.m. Eastern time.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 85459924.  To access the webcast, please log on to the company's website at at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call.  The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 85459924.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone, for which InterMune has completed the Phase 3 CAPACITY program in patients with IPF.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).  The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 and ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program.  For additional information about InterMune and its R&D pipeline, please visit

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
2. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
3. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
4. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
5. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
6. InterMune to Present at Deutsche Bank Biotech Confab
7. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
8. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
9. InterMune to Present at JMP Securities Conference
10. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
(Date:11/25/2015)... November 25, 2015 --> ... sie eine Lizenz für das Patent über eine neue ... und ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... ins Leben gerufenen und von Edelris gemeinsam mit seinen ... ein Behandlungsziel für HBV identifiziert, und es wurden neue ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of ... weight gain, cold hands, and dry skin. But many people who find their cholesterol ... exercise regimen instead of their thyroid, especially if they don’t have any of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD and ... of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses ... a dentist in Gettysburg, PA . From routine visits to cosmetic treatments, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety of ... and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ . ... WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during treatment ...
Breaking Medicine News(10 mins):